202 related articles for article (PubMed ID: 28683461)
1. Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records.
McKay KA; Evans C; Fisk JD; Patten SB; Fiest K; Marrie RA; Tremlett H
Neuroepidemiology; 2017; 48(3-4):124-130. PubMed ID: 28683461
[TBL] [Abstract][Full Text] [Related]
2. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
3. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
Kleinman NL; Beren IA; Rajagopalan K; Brook RA
J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
[TBL] [Abstract][Full Text] [Related]
4. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
[TBL] [Abstract][Full Text] [Related]
5. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
Agashivala N; Wu N; Abouzaid S; Wu Y; Kim E; Boulanger L; Brandes DW
BMC Neurol; 2013 Oct; 13():138. PubMed ID: 24093542
[TBL] [Abstract][Full Text] [Related]
6. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
McKay KA; Tremlett H; Patten SB; Fisk JD; Evans C; Fiest K; Campbell T; Marrie RA;
Mult Scler; 2017 Apr; 23(4):588-596. PubMed ID: 27357507
[TBL] [Abstract][Full Text] [Related]
7. Adherence to Disease-Modifying Therapies at a Multiple Sclerosis Clinic: The Role of the Specialty Pharmacist.
Banks AM; Peter ME; Holder GM; Jolly JA; Markley BM; Zuckerman SL; Choi L; Nwosu S; Zuckerman AD
J Pharm Pract; 2020 Oct; 33(5):605-611. PubMed ID: 30700202
[TBL] [Abstract][Full Text] [Related]
8. Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis.
Zuckerman AD; DeClercq J; Simonson D; Zagel AL; Turco E; Banks A; Wawrzyniak J; Rightmier E; Blevins A; Choi L
Mult Scler Relat Disord; 2023 Jul; 75():104738. PubMed ID: 37182475
[TBL] [Abstract][Full Text] [Related]
9. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.
Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D
J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292
[TBL] [Abstract][Full Text] [Related]
10. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.
Burkhard A; Toliver J; Rascati K
J Manag Care Spec Pharm; 2021 Jul; 27(7):915-923. PubMed ID: 34185555
[No Abstract] [Full Text] [Related]
11. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.
Evans C; Marrie RA; Zhu F; Leung S; Lu X; Kingwell E; Zhao Y; Tremlett H
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):702-711. PubMed ID: 28370875
[TBL] [Abstract][Full Text] [Related]
12. Multiple modality approach to assess adherence to medications across time in Multiple Sclerosis.
Neter E; Wolkowitz A; Glass-Marmor L; Lavi I; Ratzabi S; Leibkovitz I; Miller A
Mult Scler Relat Disord; 2020 May; 40():101951. PubMed ID: 32004857
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
Lenz F; Harms L
Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
[TBL] [Abstract][Full Text] [Related]
14. Assessing medication adherence in inflammatory bowel diseases. A comparison between a self-administered scale and a pharmacy refill index.
de Castro ML; Sanromán L; Martín A; Figueira M; Martínez N; Hernández V; Del Campo V; Pineda JR; Martínez-Cadilla J; Pereira S; Rodríguez Prada JI
Rev Esp Enferm Dig; 2017 Aug; 109(8):542-551. PubMed ID: 28679280
[TBL] [Abstract][Full Text] [Related]
15. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression.
Mardan J; Hussain MA; Allan M; Grech LB
J Manag Care Spec Pharm; 2021 Sep; 27(9):1273-1295. PubMed ID: 34464209
[No Abstract] [Full Text] [Related]
16. Adherence and persistence to drug therapies for multiple sclerosis: A population-based study.
Evans C; Marrie RA; Zhu F; Leung S; Lu X; Melesse DY; Kingwell E; Zhao Y; Tremlett H
Mult Scler Relat Disord; 2016 Jul; 8():78-85. PubMed ID: 27456879
[TBL] [Abstract][Full Text] [Related]
17. Measures of adherence based on self-report exhibited poor agreement with those based on pharmacy records.
Guénette L; Moisan J; Préville M; Boyer R
J Clin Epidemiol; 2005 Sep; 58(9):924-33. PubMed ID: 16085196
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
[TBL] [Abstract][Full Text] [Related]
19. Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis.
Zaheer R; Amin R; Riddick L; Roy S; Wolff S; Nathanson A; Newsome S
Mult Scler Relat Disord; 2023 Mar; 71():104575. PubMed ID: 36857853
[TBL] [Abstract][Full Text] [Related]
20. Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
Ha-Vinh P; Nauleau S; Clementz M; Régnard P; Sauze L; Clavaud H
Presse Med; 2019 Jan; 48(1 Pt 1):e1-e19. PubMed ID: 30528148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
